Thirdly, due to the retrospective nature of the study, certain molecular markers in patients were not assessed, such as PD-L1 expression and tumor mutation burden (TMB), thus preventing analysis of these markers’ predictive value for treatment efficacy. This evidence concerns the gene CD274 and neoplasm.